Exhibit 99.1  Gemini Therapeutics Reports Second Quarter 2021 Financial Results

| | • | | *Initial data from ongoing Phase 2a study in geographic atrophy demonstrated ability of GEM103 to durably regulate complement and showed a differentiated safety profile with no increased risk of CNV* | | --- | --- | --- | --- |

This is the opening of the release as filed. Read the full document on SEC.gov, or read it in full on SPAC Watch with the trust, deadline and warrant terms alongside it.